Sunho Pharmaceutical

Sunho Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the development of innovative immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary Armed-ImmunoCytokine (AIC) and Bifunctional Antibody-Cytokine (BAC) platforms to create next-generation biologics, including antibody-cytokine fusion proteins and bispecific antibodies. Its lead candidates, such as IAP0971 and IAE0972, are designed to enhance the anti-tumor immune response by delivering potent cytokines directly to the tumor microenvironment while minimizing systemic toxicity. Sunho successfully listed on the Hong Kong Stock Exchange in 2024 to accelerate the clinical development of its diverse pipeline. The company's approach focuses on overcoming the historical challenges of cytokine therapy through targeted delivery and improved safety profiles.